Upfront therapy: the case for continuous treatment-Reference-Cited by-同舟云学术

Upfront therapy: the case for continuous treatment

Published:2021-12-10 Issue:1 Volume:2021 Page:55-58
ISSN:1520-4391
Container-title:Hematology
language:en
Short-container-title:

Author:

Tam Constantine S.¹

Affiliation:

1. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia; and The Royal Melbourne Hospital, Parkville, Victoria, Australia

Abstract

Abstract Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/hematology/article-pdf/2021/1/55/1851744/55tam.pdf

Reference43 articles.

1. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia;Tam;Blood,2008

2. Ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

3. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study;Byrd;Clin Cancer Res,2020

4. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia;Keating;Leuk Lymphoma,2002

5. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy;Tam;Leuk Lymphoma,2007

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease;Current Oncology Reports;2024-01-04